Acimmune SA

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company designs, discovers, and develops therapeutic and diagnostic products aimed at prevention, diagnosis, and treatment of these conditions. Its proprietary technology platforms, SupraAntigen and Morphomer, enable the creation of antibodies, small molecules, active immunotherapies, and vaccines targeting a broad range of neurodegenerative disorders. AC Immune SA maintains a diversified pipeline featuring multiple clinical-stage candidates, such as ACI-7104, an anti-α-synuclein active immunotherapy for early Parkinson’s disease, ACI-24 and ACI-35 in pharmaceutical collaborations, and small molecule programs including brain-penetrant NLRP3 inhibitors like ACI-19764 and Tau aggregation inhibitors. The company collaborates with leading global pharmaceutical partners, including Janssen Pharmaceuticals, Takeda, Eli Lilly and Co., and others, to advance its programs. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA plays a significant role in addressing the growing challenges of neurodegeneration through innovative therapeutic and diagnostic solutions.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Andrea Pfeifer Ph.D.

Employees

90

Headquarters

Lausanne, Switzerland

Website

www.acimmune.com